77 Participants Needed

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Recruiting at 20 trial locations
NP
Overseen ByNovartis Pharmaceuticals
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Novartis Pharmaceuticals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug called KAZ954 alone and with other drugs to find the safest and most effective dose for patients with advanced cancer. The goal is to see if these treatments can help patients who haven't responded to standard therapies.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Who Is on the Research Team?

NP

Novartis Pharmaceuticals

Principal Investigator

Novartis Pharmaceuticals

Are You a Good Fit for This Trial?

Inclusion Criteria

ECOG Performance Status of <2.
You have advanced cancer that cannot be treated with surgery to cure it.
Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening and during the study.

Exclusion Criteria

You have experienced a severe allergic reaction to any ingredient in the study drug or similar medications.
There may be additional requirements or restrictions for participating in the study that are not listed here.
You have heart problems, HIV, a history of tuberculosis, or have been taking steroids for a long time.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

The dose escalation part estimated the MTD and/or RD and tested different dosing schedules.

Up to 52 weeks

Dose Expansion

Planned to use the MTD/RDE determined in the dose escalation part to assess the activity, safety, and tolerability of the investigational products.

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • KAZ954
  • NIR178
  • NZV930
  • PDR001
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Arm DExperimental Treatment2 Interventions
Group II: Arm CExperimental Treatment2 Interventions
Group III: Arm BExperimental Treatment2 Interventions
Group IV: Arm AExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Novartis Pharmaceuticals

Lead Sponsor

Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan profile image

Dr. Vas Narasimhan

Novartis Pharmaceuticals

Chief Executive Officer since 2018

MD from Harvard Medical School

Dr. Shreeram Aradhye profile image

Dr. Shreeram Aradhye

Novartis Pharmaceuticals

Chief Medical Officer since 2021

MD

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security